Telomir Pharmaceuticals Reports Preclinical Telomir-Zn Improves Visual Function and Retinal Structure in AMD Model
Found this article helpful?
Share it with your network and spread the knowledge!
Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced the peer-reviewed publication of preclinical research showing that its lead small-molecule therapeutic, Telomir-Zn, significantly improved visual function, restored retinal structure, and reduced mitochondrial oxidative stress in a model of age-related macular degeneration (AMD). The study appeared in the International Journal of Molecular Sciences and also reported that treatment was associated with the restoration of altered DNA methylation patterns and a dose-dependent increase in relative telomeric DNA content toward levels seen in healthy animals. These results suggest that Telomir-Zn may address fundamental mechanisms of cellular aging and degeneration.
The AMD study further showed that Telomir-Zn reduced intracellular labile iron and inhibited iron-dependent Jumonji C histone demethylases, providing a potential mechanistic link between intracellular metal modulation and epigenetic regulation. This dual action on metal homeostasis and epigenetic pathways is central to the company's approach. While the preclinical data highlight potential in ophthalmology, Telomir Pharmaceuticals remains focused on oncology. Its lead program, Telomir-Zn, is advancing under an FDA-cleared Investigational New Drug application for a Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer.
For Texas, the news underscores the state's growing role in biotechnology innovation. Telomir Pharmaceuticals is not explicitly headquartered in Texas, but BioMedWire, the platform distributing this news, is based in Austin. As a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, BioMedWire's presence in Austin highlights the city's expanding ecosystem for health-related industries. The company is one of more than 75 brands within the Dynamic Brand Portfolio @ IBN, which provides wire solutions, article and editorial syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications. This infrastructure helps Texas-based and national biotech firms reach investors, influencers, and the public.
The implications of the Telomir-Zn findings extend beyond AMD. If the mechanism of modulating intracellular metal homeostasis and epigenetic regulation proves safe and effective in humans, it could lead to new treatments for a range of age-related and degenerative conditions. The ongoing Phase 1/2 trial in triple-negative breast cancer will be a critical test of the drug's clinical potential. For investors and industry observers, the publication in a peer-reviewed journal adds scientific credibility and may accelerate interest in Telomir's platform. For patients, the research offers a glimmer of hope for diseases with limited treatment options.
To view the full press release, visit https://ibn.fm/iUtFx. The latest news and updates relating to TELO are available in the company's newsroom at https://ibn.fm/TELO. For more information about BioMedWire, visit https://www.BioMedWire.com. Terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.